, a presynaptic adhesion molecule, localizes at the slit diaphragm of the glomerular podocytes in kidneys. Am
THE CAPILLARY WALL OF KIDNEY glomeruli consists of three layers: endothelial cells, glomerular basement membrane, and glomerular visceral epithelial cells (podocytes). Podocytes are characterized by their unique cell shape with the interdigitating foot processes that cover the basement membrane (22) . Neighboring foot processes are derived from different cell bodies and are connected by a continuous membrane-like structure called the slit diaphragm (38) . Since the 1980s, we have been proposing that the slit diaphragm plays a critical role in maintaining the barrier function of the glomerular capillary wall (9, 16 -18, 30 -32) . In 1998, nephrin was identified as a molecule of the product of the gene mutated in Finnish-type congenital nephrotic syndrome and was demonstrated to be a component of the slit diaphragm (19, 40) . Several recent studies with experimental models and clinical materials showed that the slit diaphragm plays a critical role in maintaining the barrier function of the glomerular capillary wall (9, 17, 18) . It is gradually being accepted that proteinuria in several kinds of glomerular diseases resulted from slit diaphragm dysfunction (1, 16, 24, 29, 33, 41) .
Several molecules such as nephrin, podocin, and CD2AP have been identified as components of the slit diaphragm (4, 6, 7, 13, 36, 37, 42, 48) . It is understood that nephrin, a key molecule of the slit diaphragm, interacts with other components. We have previously reported that the expression of nephrin and podocin is clearly lowered in glomeruli of puromycin aminonucleoside (PAN) nephropathy, a model of human minimal change nephrotic syndrome, and proposed that the decrease in the levels of these molecules contributes to the development of proteinuria (9, 16, 17) . We have also reported that nephrin was dissociated from podocin at the very early phase in this disease (18) . In Heymann nephritis, an experimental model of membranous nephropathy, it was observed that nephrin was dissociated from podocin and CD2AP at the early phase before the onset of proteinuria (30) . Recently, we reported that the dissociation of NEPH1, another component of the slit diaphragm, from nephrin is a critical event of the early phase of adriamycin-induced nephropathy, a mimic of focal segmental glomerulosclerosis (32) . All of these observations showed that the disarrangement of the slit diaphragm components leads to proteinuria in these diseases.
It has been pointed out that podocytes and neurons have common characteristics (20) . Both are terminally differentiated cells and have similar shapes characterized by processes. Both also display cell-type-specific intercellular contact: 1) synapses in neurons and 2) the slit diaphragm in podocytes. Thus, to analyze whether the functionally important molecules in the synapse are expressed in the podocytes and to clarify their function in the podocytes are a rational strategy to better understand the molecular composition of the slit diaphragm. We have previously reported that the synaptic vesicle protein 2B was expressed in podocytes, and its expression clearly decreased in injured podocytes (27) . Rastaldi et al. (35) have reported that the synaptic vesicle molecule Rab3A was expressed in podocytes. These observations suggest that synaptic vesicle-like vesicles play an important role in maintaining podocyte function.
Neurexins are reported to interact with the synaptic vesicleassociated molecules, and are postulated to play a role in synaptic vesicle docking (11, 34) . It is also known that neurexins are a presynaptic transmembrane protein and have a major role in cell-cell interactions across the synapse (47) . Neurexins are reported to bind CASK, a member of the membrane-associated guanylate kinase (MAGUK) family (11) , via a PDZ-binding site in the intracellular domain of neurexin. Recently, CASK was reported to be expressed in podocytes and to interact with nephrin (23) . These properties of neurexin prompted us to hypothesize that neurexin is expressed in podocytes and is involved in the maintenance of podocyte function. To elucidate this hypothesis, we analyzed the expression of neurexin in kidney glomeruli.
In the present study, we demonstrated that neurexin is restrictedly expressed in podocytes in kidneys and that neurexin is localized at the cytoplasmic area around the slit diaphragm. We also showed that the expression of neurexin is clearly lowered in the injured podocytes. These findings suggest that neurexin is associated with the slit diaphragm.
MATERIALS AND METHODS
Animals. Specific pathogen-free, 7-wk-old female Wistar rats (Charles River Japan, Atsugi, Japan) weighing 150 -170 g were used for the induction of the experimental models. Normal rats were killed, and the organs (cerebrum, cerebellum, medulla oblongata, thymus, lung, heart, stomach, pancreas, spleen, liver, adrenal, whole kidney, colon, small intestine, uterus, ovary, placenta, testes, bladder, skin and muscle) were removed. The materials were used for immunofluorescence and RT-PCR. All animal experiments conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All procedures for the present study were approved by the Animal Committee at Niigata University School of Medicine, and all animals were treated according to the guidelines for animal experimentation of Niigata University.
Metanephroi, cultured podocytes, human kidney sections. Metanephroi were removed from rats of 13.5, 15.5, and 18.5 embryonic days and from neonatal rats. A conditionally immortalized mouse podocyte cell line was kindly donated by Dr. Peter Mundel (Albert Einstein College of Medicine, Bronx, NY). Cultivation of the cell was conducted as described previously (28) . In brief, podocytes were maintained in RPMI 1640 medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% FBS (Life Technologies, Grand Island, NY). To propagate podocytes, cells were first cultivated at 33°C with IFN-␥ and maintained for 2 wk at 37°C to induce differentiation without IFN-␥. The human kidney specimen used for immunofluorescence study was isolated from the normal part of kidney tissue that had been obtained from nephrectomy of a previous study.
Experimental nephrotic models. To induce PAN nephropathy, a total of 24 rats were intravenously injected with 10 mg/100 g body wt of PAN. Six rats each were killed just before the injection 1 h, 24 h, 10 days, and 28 days after injection. Twenty-four-hour urine samples were collected on 1, 3, 5, 7, 10, 14, and 28 days after injection.
Anti-nephrin antibody (ANA)-inducing nephropathy was prepared by an intravenous injection with 15 mg/rat or mouse anti-nephrin monoclonal antibody (mAb 5-1-6) (17, 31, 44) . A total of 24 rats were injected, and six rats each were killed 1 h, 24 h, 5 days, and 20 days after injection. Twenty-four-hour urine samples were collected on 1, 3, 5, 7, 14, and 20 days after injection. Urinary protein concentrations were measured by colorimetric assay with Protein Assay Reagent (Bio-Rad) using bovine serum albumin as a standard. In both models, small tissue samples were used for immunofluorescence studies. To prepare two sets of glomerular RNA in each time point, glomeruli were isolated from the remaining kidney tissue pooled from three rats each by a sieve method (21) , and glomerular RNA was prepared with Trizol. To prepare another set of glomerular RNA, three rats were injected with PAN, and kidneys were removed at 24 h after the injection.
Immunohistochemistry. Immunohistochemical studies were performed basically according to the method previously reported (17) . The 3-m-thick sections with cryostat of frozen rat and human materials or cultured podocytes on glass coverslips were fixed with acetone for 1 min at room temperature and incubated at 37°C for 30 min and at 4°C overnight with rabbit anti-neurexin antibody (reactive to amino acids 1109 -1123; WPANDRPSTRSDRLA) (Calbiochem, San Diego, CA) and stained with FITC-conjugated swine anti-rabbit IgG (DAKO, Glostrup, Denmark) at 37°C for 30 min. The antineurexin antibody recognized both neurexin-1␣ and -1␤. The sections were observed with immunofluorescence microscopy (BX-50; Olympus, Tokyo). The specificity of anti-neurexin antibody was confirmed by preabsorption analysis with a peptide used for preparation of this antibody. The peptide for preabsorption analysis was purchased from GenScript (Scotch Plains, NJ). To evaluate the alterations of neurexin staining in the injured rat glomeruli, the staining was graded semiquantitatively as follows: continuous staining of Ͼ 75% of the area of the capillary loops was graded 4; 50 to 75% was graded 3; 25 to 50% was graded 2; and 0 to 25% was graded 1. A score was assigned to each glomerulus, and more than 30 glomeruli of each rat were analyzed. The final score was shown as the mean. To analyze the localization of neurexin in glomeruli, the dual-labeling immunofluorescence study was performed basically according to the method of the previous report (10) . The following primary antibodies were used to detect the glomerular cell markers: 1) mouse anti-rat endothelial cell antigen-1 (RECA-1) antibody (Serotec, Oxford, UK); 2) mouse monoclonal antibodies to Thy 1.1, a mesangial cell marker (mAb 1-22-3) (15); and 3) mouse mAb against nephrin, a podocyte marker (mAb 5-1-6), goat antibody against CD2AP, a podocyte marker (Santa Cruz, CA). The secondary antibodies were used as follows: 1) tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-mouse IgG1 (Southern Biotechnology Associates) for anti-RECA-1 and mAb 5-1-6; 2) TRITC-conjugated goat anti-mouse IgG3 (Southern Biotechnology Associates) for mAb 1-22-3; and 3) TRITCconjugated donkey anti-goat IgG (Protos Immunoresearch, San Francisico, CA) for anti-CD2AP.
Real-time RT-PCR. Real-time RT-PCR was performed as described previously (30) . The reactions and runs were performed three times for each sample. To prepare standard materials, PCR products of neurexin-1␣, neurexin-1␤, and GAPDH were subcloned into the plasmid vector pCRII-TOPO, and the plasmids were diluted from 1ϫ10 2 copies to 1ϫ10 9 copies to generate calibration curves, which were based on the linear relationship between the crossing point cycle values and the logarithm of the starting copy number.
Interaction assays. Glomerular lysate solubilized with 1% Triton X-100 with protease inhibitors cocktail (Bio-Rad) was incubated with anti-neurexin antibody (SYSY) at 4°C overnight and precipitated with Dynabeads Protein G (Invitrogen, Carlsbad, CA). The tube was placed on the magnet, and the supernatant was removed. The Dynabeadsantibody-antigen complex was washed 5 times with PBS containing 0.1% Triton X-100, and then the antigen was eluted with SDS-PAGE sample buffer. The elution fractions were separated by SDS-PAGE followed by immunoblotting with goat anti-CD2AP antibody and mouse anti-CASK/LIN-2 (Zymed Labolatory, San Francisco, CA). Alkanline phosphatase-conjugated rabbit anti-goat IgG and rabbit anti-mouse IgG (Science Bio) were used to detect CD2AP and CASK, respectively.
Analyses of splice variants expression. Neurexin-1␣ has five splice sites in its extracellular site [splice site 1: amino acid 258 -277, splice site 2: 379 -393, splice site 3: 790 -799, splice site 4: 1247-1276, splice site 5: 1410 -1411 of rat neurexin-1␣ (accession no. Q63373)], and it is reported that several splice variants of neurexin-1␣ were detected in some tissues. To analyze the expression of the splice variants at sites 1-5 of rat glomeruli and cerebrum, the specific primers for neurexin-1␣ were designed as follows: to detect splice site 1 (sense, 5=-GAG GAC CGG TTT CCG TGG CAA AGA C-3=; antisense, 5=-CGC TTC AAA GGC CCC TGA TCC C-3=); splice site 2 (sense, 5=-GGG ATC AGG GGC CTT TGA AGC G-3=; antisense, 5=-CAT CTG CGG GTG CTT GGC ATC CTT C-3=); splice site 3 (sense, 5=-GGA ACA GAT ACG TCT GTG ATT GCT C-3=; antisense, 5=-GCC ACT GAT TGT CGT TGA GTG G-3=); and splice sites 4 and 5 (sense, 5=-GCC AGT CAT CGA ACG ATA CC-3=; antisense, 5=-CAT CCC GGT TTC TGT ACT TG-3=). The size of the bands of the PCR products was analyzed. To analyze whether the PCR products contain the splice sites 2, 4, and 5, cDNA of the PCR products containing these sites were sequenced. The sequencing was performed basically in accordance with the method previously reported (18) . The PCR products were cloned into a TOPO Vector (Invitrogen), and DNA sequences were determined by an automated DNA sequencer (ABI 310; Perkin-Elmer Japan, Urayasu, Japan).
RESULTS

Detection of mRNA expression of neurexin-1␣ and -1␤ in several organs and tissues.
The mRNA expression for neurexin-1␣ and -1␤ was detected in several rat organs and tissues of normal adult rat. No neurexin-1␣ signals could be detected in the rat pancreas or spleen (Fig. 1) . The mRNA expression of neurexin-1␣ in whole kidney material is more extensive than that in the glomeruli, whereas the expression of neurexin-1␤ in the whole kidney material is less than that in the glomeruli.
Neurexins are expressed in podocytes. Neurexin staining in the kidney was restricted to the glomeruli, and it was found to be a discontinuous linear pattern along the glomerular capillary loops. No staining was observed in normal rabbit serum and in anti-neurexin antibody preabsorbed with the immunizing peptide ( Fig. 2A) . To analyze the localization of neurexins in the glomeruli, a dual-labeling immunofluorescence study was carried out with the following glomerular-cell markers: 1) the endothelial-cell marker RECA-1, 2) the mesangial-cell marker Thy 1.1 (mAb 1-22-3), and 3) the podocyte slit diaphragm marker nephrin (mAb 5-1-6). Neurexins were not observed in endothelial cells or mesangial cells but were present in podocytes (Fig. 2B) . The localization of neurexins coincided almost completely with that of CD2AP. The neurexin staining did not coincide with nephrin staining in normal adult rat glomeruli.
The mRNA expression of neurexin-1␣ and -1␤ was already detected in embryonic kidney samples on embryonic date 13.5 (E 13.5), although no positive staining was detected with immunohistochemical analysis. Neurexin staining was first detected in the presumptive podocytes of the capillary loopstage glomeruli. The staining was detected at the basal surface of podocytes, and was colocalized with nephrin (Fig. 2C) . The mRNA expression of neurexin-1␣ and -1␤ was detected in mouse-cultured podocytes.
Neurexin staining was observed along the glomerular capillary loops in human kidney sections in a similar pattern to that in the adult rat section (Fig. 3) .
Neurexins in podocytes have an interaction with CD2AP and CASK. Specific bands for CD2AP and CASK were detected in the precipitated material of anti-neurexin antibody (Fig. 4) .
Expression of a single form of the splice variants of neurexin-1␣ in rat glomeruli. The PCR products of neurexin-1␣ containing the splice sites 1-5 from glomeruli and cerebrum are shown in Fig. 5A . In the analysis of the splice site 2, a single band of a PCR product without an insert was detected in the glomerular RNA, and two bands of the PCR products with and without the insert were detected in the cerebrum RNA. Amino acid sequences of these PCR products are shown in Fig.  5B . The PCR products of the glomeruli and cerebrum from the lower band completely lacked the splice site 2. In the analyses of the splice sites 1 and 3, a single band of insert plus was detected in the PCR products from both the glomerular and the cerebrum RNA materials. Two bands of the PCR products with and without an insert at the splice site 4 were detected in the mRNA from the cerebrum, but only a single band of the PCR product with the insert was detected in the glomerular RNA. It was confirmed by sequencing analysis that amino acids at the splice sites 4 and 5 were contained in the PCR product from glomerular RNA (Fig. 5B) . The nucleotide sequences of the intracellular site of neurexin-1␣ of the glomerular sample were completely identical to those of the cerebrum sample.
Expression of neurexins is altered in injured podocytes. The kinetics of proteinuria in PAN nephropathy and ANA nephropathy are shown in Fig. 6D . The representative immunofluorescence findings of neurexin in PAN and ANA nephropathy are shown in Fig. 6A . In PAN nephropathy, a decrease in neurexin staining was already detected at 24 h. The staining intensity was clearly reduced, and the staining pattern changed to a more discontinuous fine granular pattern on day 10, when proteinuria peaked. On day 28, when proteinuria was normalized, the staining intensity was not yet completely recovered. The staining pattern of neurexin on day 28 was linear at the basal surface Fig. 1 . RT-PCR findings of neurexin-1␣ and -1␤ in several normal rat organs and tissues. The mRNA expression of neurexin-1␣ and -1␤ were detected not only in neuronal tissues but also in several major organs, including kidney, heart, and lung. No neurexin-1␣ signal was detected in the rat pancreas or spleen.
of podocytes. The dual-labeling study showed that the neurexin staining on day 28 was colocalized with nephrin ( Fig. 6C) . In ANA nephropathy, the intensity of the neurexin staining decreased, and the staining pattern changed to become a more discontinuous pattern at 24 h. Almost no signal was detected in some glomeruli of rats on day 5, when the proteinuria peaked. Nephrin staining shifted to a discontinuous coarse granular pattern, and its staining intensity decreased on day 10 of PAN nephropathy and on day 5 of ANA nephropathy. The intensity of the nephrin staining was almost recovered on day 28 of PAN nephropathy and on day 20 of ANA nephropathy. No clear alteration was observed in the podocalyxin staining in PAN or ANA nephropathy. The results of our semiquantitative evaluation of the neurexin staining are shown in Fig. 6B .
The mRNA expression of neurexin-1␣ and -1␤ in PAN nephropathy was analyzed by real-time RT-PCR. The results were shown in Fig. 7 . The mRNA expression of both neurexins was clearly decreased at 24 h after PAN injection. Neurexin-1␣ deceased to 5.0%, and neurexin-1␤ deceased to 21%.
DISCUSSION
Neurexins are type I membrane proteins that have been classified into two types, ␣ and ␤. Neurexin-1␣, the first neurexin identified, was isolated as a brain protein that bound to ␣-latrotoxin, a component of black widow spider venom. The other neurexins were discovered subsequently by virtue of their sequence similarity to neurexin-1␣. Because it has been accepted that neurexins are neuronal cell-specific proteins (46) , their expression in other tissues has not been precisely analyzed. In this study, we started to analyze the expression of neurexins in major organs. We found that neurexins were expressed not only in the neuronal tissues but also in several organs, including kidneys, lung, and colon (Fig. 1) . We then analyzed the localization of neurexins in the kidney. Immunohistochemical studies demonstrated that neurexins are restrictedly expressed in the glomeruli in kidney. Neurexins in glomeruli were observed along the glomerular capillary loop as a podocyte pattern (Fig. 2) . Dual-labeling studies with glomerular cell markers showed that neurexins were clearly apart from endothelial cell and mesangial cell markers. These observations showed that neurexins are expressed in podocytes. We observed with dual labeling immunofluorescence techniques that neurexins are colocalized with CD2AP, a component of the slit diaphragm (42) (Fig. 2) . The immunoprecipitation assay with glomerular lysate demonstrated that neurexins have an interaction with CD2AP. We also confirmed that neurexins interact with CASK, a MAGUK family protein (Fig. 4) . Neurexins have the four amino acid tail that functions as a recognition sequence for the PDZ domains of MAGUK. We confirmed that these four amino acids were conserved in the neurexin-1␣ cDNA synthesized from glomerular RNA. It is plausible that neurexins of the podocytes interact with Fig. 2 . Expression of neurexin in normal adult rat glomeruli and in the developing glomeruli. A: immunofluorescence finding of neurexin in adult rat kidney section. Neurexin staining was restricted to the glomeruli, and the staining was observed as a discontinuous linear pattern along the glomerular capillary loops. No staining was observed with normal rabbit serum (NRS) nor with the anti-neurexin antibody preabsorbed with the immunizing peptide. Bars, 50 m. B: dual-labeling immunofluorescence findings of neurexin (green staining) with the glomerular-cell markers (red staining). Neurexin staining was clearly apart from endothelial cell marker rat endothelial cell antigen-1 (RECA-1) (arrow) and mesangial-cell marker Thy 1.1 (arrow). Neurexin staining was slightly apart from nephrin staining (arrow) and coincided with CD2AP staining, and this overlay figure showed yellow staining. Insets, high-power magnification of the area indicated by the arrows. C: expression of neurexins in the developing kidney. The staining of neurexin was observed at the basal surface of a presumptive podocyte in the late capillary loop stage glomeruli of a neonatal rat (arrow). Bar, 25 m. Staining of neurexin (green) almost coincided with nephrin staining (red). The mRNA expression of neurexin-1␣ and -1␤ was already detected in embryonic kidney sample on embryonic day 13.5 (E 13.5), CASK via this site. Both CD2AP and CASK are reported to interact with nephrin. These results suggest that neurexins are components of the slit diaphragm.
To elucidate the function of neurexin in the slit diaphragm, we analyzed the expression of neurexins in podocytes of the developing glomeruli and in the injured glomeruli. The mRNA expression of neurexins was already detected in the developing glomeruli on the embryonic date of 13.5, although their immunohistological expressions are not detected in the kidney tissue of this material. Because neurexins are not densely deposited in this stage, it is hard to detect the expression with immunohistochemical methods. The immunohistological expression of neurexins in the presumptive podocytes was first detected in the late capillary loop stage when the slit diaphragm structure is actively formed. The staining was detected at the basal surface of the podocytes that coincide with nephrin. For the analyses of the expression of neurexins in the injured podocytes, we adopted two proteinuric models: 1) PAN nephropathy, a mimic human minimal change nephrotic syndrome and 2) an ANA-induced nephropathy, which is a model of a pure slit diaphragm dysfunction. The intensity of the immunostaining of neurexins was clearly lowered in PAN nephropathy on day 10 when severe proteinuria was detected. An alteration in the expression of neurexins was also detected in ANA-induced nephropathy. It should be noted that the alteration in neurexin expression is more rapid and clearer than that of nephrin staining even in the ANA-induced nephropathy. These observations show that neurexin can be an early sensitive marker to detect slit diaphragm injury. Neurexin is understood to be a presynaptic transmembrane protein and has a major role in cell-cell interactions across the synapse (47) . The observations in the present study together with the reports of neurexin in the neuronal field suggest that neurexin is involved in the maintenance of the slit diaphragm, a podocyte-specific cell-cell interaction.
It is gradually becoming accepted that synaptic vesicle-like vesicles are expressed in a variety of cells and that these vesicles play a role in the molecular trafficking of cell-surface proteins. We and another group have reported that the synaptic vesicle-associated molecules were expressed in podocytes (8, 27, 35) . It is reported that neurexins interact with synaptic vesicle-associated molecules (12, 34, 49) . These observations Fig. 6 . Expression of neurexin, nephrin, and podocalyxin in puromycin aminonucleoside (PAN) and anti-nephron antibody (ANA) nephropathy. A: kinetic change of immunofluorescence findings. A decrease in neurexin staining was already detected at 24 h of PAN nephropathy (a2). Staining intensity was clearly reduced, and the staining pattern changed to a more discontinuous fine granular pattern on day 10 (a3). On day 28, staining intensity recovered in some glomeruli, and staining was mainly observed at the basal surface of the podocyte in a linear pattern (arrow) (a4). In ANA nephropathy, the intensity of the neurexin staining decreased and the staining pattern changed to a more discontinuous pattern at 24 h (a5). Almost no signal was detected on day 5 (a6). The nephrin staining pattern shifted to a discontinuous coarse granular pattern, and its staining intensity decreased on day 10 of PAN nephropathy (b3) and day 5 of ANA nephropathy (b6). No clear alteration was observed in the podocalyxin staining at any time point examined in both models (c1-7). Bar, 50 m. B: semi-quantitative evaluation of the neurexin staining. The score was shown as mean Ϯ SD (*P Ͻ 0.05). Top: representative immunofluorescence finding of each score. C: dual-labeling immunofluorescence finding of neurexin with nephrin. The neurexin staining at basal surface of podocyte was very close to that of nephrin on day 28 of PAN nephropathy (arrow). D: kinetics of proteinuria of PAN nephropathy and ANA nephropathy.
suggest that neurexins in podocytes have an association with synaptic vesicle molecules and have a role in intracellular trafficking. In the present study, we showed that although the localization of neurexins is slightly apart from nephrin in normal adult glomeruli (Fig. 2B) , the localization of neurexins coincided with that of nephrin in glomeruli on day 28 of PAN nephropathy when the slit diaphragm was under reconstruction (Fig. 6) . We also observed that neurexin staining coincided with nephrin in the presumptive podocytes of the developing glomeruli (Fig. 2C ). These observations suggest that neurexin plays a role in the intracellular trafficking of the slit diaphragm components.
The characteristic molecular nature of neurexins is that they exhibit a striking number of alternative splicing variants (26, 39, 43) . Neurexins have three genes (neurexin-1, -2, and -3), each of which has two promoters, ␣ and ␤. The constituents of neurexin-␣ comprise three overall repeats, a central epidermal growth factor-like sequence: 1) LNS (widespread sequence motifs in laminin A, neurexin, and sex hormone-binding globulin) domains; 2) an O-linked sugar attachment sequence (a single transmembrane region); and 3) a COOH-terminal cytoplasmic sequence. Neurexin-␤ has a short sequence and contains a single LNS domain, an O-linked sugar attachment sequence, a single transmembrane region, and a COOH-terminal cytoplasmic sequence (25) . Neurexin-␣ has five splice sites (sites 1-5) and neurexin-␤ has two (sites 4 and 5) (46) . Although it is reported that the splice variants have different ligands and play different roles, the localization and the role of each variant are not well understood. In this study, we found that only one form of neurexin-1␣ is expressed in glomeruli. Many forms of splice variants of neurexin-1␣ were detected in neuronal tissues, which suggests that the finding in glomeruli is unique. The form of neurexin with the motifs of the splice sites 1, 3, 4, and 5 and without the motif of the splice site 2 expressed in glomeruli may play a differential role in podocytes.
We confirmed that neurexin is expressed in the podocytes of the human kidney (Fig. 3) . The identity of the amino acid sequence of neurexins between humans and rats is higher than 95% (45, 47) . We believe that the findings on neurexins observed with rat materials are basically compatible with those of human neurexins. Further investigation of neurexins may provide a novel diagnostic method for glomerular diseases and may enable the establishment of a novel therapy for proteinuria. In summary, the present study showed that neurexin is associated with the podocyte slit diaphragm, a key structure regulating the barrier function of glomerular capillary wall. We propose that neurexin can be an early diagnostic marker to detect podocyte injury.
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